Where does Pola Pharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pola Pharma Inc. ranks #14,869 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pola Pharma Inc. hold?

Pola Pharma Inc. holds 20 US utility patents granted between 2015 and 2021, spanning 12 technology areas.

What is Pola Pharma Inc.'s Innovation Score?

Pola Pharma Inc. has an Innovation Score of 27.2 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Pola Pharma Inc. focus on?

Pola Pharma Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 18 patents, ranking #1,084 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Pola Pharma Inc.'s patent grant rate increasing or decreasing?

Pola Pharma Inc.'s recent grant velocity is -89% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Pola Pharma Inc.'s patents?

Pola Pharma Inc.'s patents average 7.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pola Pharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Pola Pharma Inc.

USPTO PatentsView assignee record - 20 granted patents across 12 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pola ranks #14,869 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 12 technology areas.

#14,869
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.2/100): 7.4
avg claims per patent: -89%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14869 · Foreign Corporation #14,869 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 20 grants
MID-PACK #14,869/49,997
PHOTO-FINISH Pacific Industrial…
CPC-FOCUS A61P · 12 areas
INNOV-THIN 27.2/100
CLAIMS-SPARSE 7.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -89% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Pacific Industrial Development Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pola’s 27.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (39%) Velocity 0.0 pts (0%) Breadth 12.2 pts (45%) Claim depth 4.4 pts (16%)

Qualcomm Incorporated · highest

85
Pola Pharma · this assignee

27
3D Lighting… · lowest

7

What this shows Pola's Innovation Score is 27.2/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pola?

Each dot is one of Pola’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pola’s own 7.4 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Pola vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pola's grants concentrate

Pola Pharma Inc. is a focused PatentsView assignee: 12 CPC subclasses with 90% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (9 grants) versus a trough of 1 in 2017. By volume, Pola sits between PHD, Inc. and Pascal Engineering Corporation.

PHD

20
PI Advanced Mater…

20
Pmc-sierra

20
Pocared Diagnosti…

20
Purpose

20
Pacific Industria…

20
Pandrol

20
Pascal Engineering

20
Pola Pharma ◀

20

What this shows Pola holds 20 patents at rank #14,848, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pola

By rank, the assignees closest to #14,848 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Pola's primary technology class.

Pola's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Pola Pharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	9	45.0%
2016	5	25.0%
2017	1	5.0%
2018	2	10.0%
2019	1	5.0%
2021	2	10.0%

Which technologies does Pola Pharma Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07D - Heterocyclic Compounds 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

B65B - Machines, Apparatus OR Devices FOR, OR Methods OF, Packaging Articles OR MATERIALS; Unpacking 1

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pola Pharma Inc.'s patent record in context - here's where to go next.

Pola Pharma Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 90% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #14,869 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pola Pharma Inc. against PHD, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.